LU92218I2 - Mirabegron ou un de ses sels - Google Patents

Mirabegron ou un de ses sels

Info

Publication number
LU92218I2
LU92218I2 LU92218C LU92218C LU92218I2 LU 92218 I2 LU92218 I2 LU 92218I2 LU 92218 C LU92218 C LU 92218C LU 92218 C LU92218 C LU 92218C LU 92218 I2 LU92218 I2 LU 92218I2
Authority
LU
Luxembourg
Prior art keywords
bladder
rat
urination
rhythmic
measurement test
Prior art date
Application number
LU92218C
Other languages
English (en)
Other versions
LU92218I9 (fr
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32310425&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU92218(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of LU92218I2 publication Critical patent/LU92218I2/fr
Publication of LU92218I9 publication Critical patent/LU92218I9/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/40—Unsubstituted amino or imino radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
LU92218C 2002-11-07 2013-06-17 Mirabegron ou un de ses sels LU92218I2 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2002323792 2002-11-07

Publications (2)

Publication Number Publication Date
LU92218I2 true LU92218I2 (fr) 2014-01-07
LU92218I9 LU92218I9 (fr) 2019-01-17

Family

ID=32310425

Family Applications (1)

Application Number Title Priority Date Filing Date
LU92218C LU92218I2 (fr) 2002-11-07 2013-06-17 Mirabegron ou un de ses sels

Country Status (28)

Country Link
US (5) US7750029B2 (fr)
EP (1) EP1559427B1 (fr)
JP (1) JP3815496B2 (fr)
KR (1) KR100967070B1 (fr)
CN (1) CN100406011C (fr)
AT (1) ATE500827T1 (fr)
AU (1) AU2003284700B2 (fr)
BE (1) BE2013C040I2 (fr)
BR (1) BR0316080A (fr)
CA (1) CA2503570C (fr)
CY (2) CY1111399T1 (fr)
DE (1) DE60336334D1 (fr)
DK (1) DK1559427T3 (fr)
ES (1) ES2360353T3 (fr)
FR (1) FR13C0032I2 (fr)
HU (1) HUS1300027I1 (fr)
IL (1) IL168121A (fr)
LU (1) LU92218I2 (fr)
MX (1) MXPA05004925A (fr)
NL (1) NL300599I2 (fr)
NO (2) NO334948B1 (fr)
NZ (1) NZ539577A (fr)
PL (1) PL211687B1 (fr)
PT (1) PT1559427E (fr)
RU (1) RU2321401C2 (fr)
SI (1) SI1559427T1 (fr)
WO (1) WO2004041276A1 (fr)
ZA (1) ZA200503510B (fr)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10351271A1 (de) * 2003-10-31 2005-06-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Zusammensetzung zur Behandlung der Stressinkontinenz und/oder Mischinkontinenz
SI2216021T1 (sl) * 2007-11-02 2013-01-31 Astellas Pharma Inc. Farmacevtski sestavek za zdravljenje prekomerno aktivnega sečnega mehurja
EP2223690A4 (fr) * 2007-12-21 2011-02-23 Astellas Pharma Inc Composition pharmaceutique utilisée pour atténuer les symptômes du tractus urinaire inférieur
PE20091825A1 (es) * 2008-04-04 2009-12-04 Merck & Co Inc Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3
TWI478712B (zh) * 2008-09-30 2015-04-01 Astellas Pharma Inc 釋控性醫藥組成物
WO2010053068A1 (fr) * 2008-11-07 2010-05-14 大日本住友製薬株式会社 Nouvel agent thérapeutique utile pour un symptôme du tractus urinaire inférieur
WO2010147830A2 (fr) * 2009-06-15 2010-12-23 Auspex Pharmaceuticals, Inc. Modulateurs aminothiazole de bêta-3-adrénorécepteur
JP5849946B2 (ja) * 2010-03-29 2016-02-03 アステラス製薬株式会社 放出制御医薬組成物
ES2665467T3 (es) 2010-03-29 2018-04-25 Astellas Pharma Inc. Composición farmacéutica de liberación modificada
US9655885B2 (en) 2011-05-18 2017-05-23 Dr. Reddy's Laboratories Ltd. Amorphous mirabegron and processes for crystal forms of mirabegron
IN2013CN09704A (fr) 2011-05-18 2015-07-03 Reddys Lab Ltd Dr
EP2832730A4 (fr) 2012-03-30 2015-09-09 Astellas Pharma Inc Composition pharmaceutique contenant du mirabegron
TW201424772A (zh) 2012-08-31 2014-07-01 Astellas Pharma Inc 經口投與用醫藥組成物
WO2014132270A2 (fr) * 2013-02-27 2014-09-04 Msn Laboratories Limited Procédé de préparation de monochlorydrate d'acétamide 2- (2-aminothiazol -4-yl)-n- [4- (2- {[ (2r) -2-hydroxy -2-phényl-éthyl] amino} éthyl) phényl], de ses intermédiaires et polymorphe de celui-ci
CN103193730A (zh) * 2013-04-17 2013-07-10 苏州永健生物医药有限公司 一种米拉贝隆的合成方法
CN103193658A (zh) * 2013-04-18 2013-07-10 苏州永健生物医药有限公司 一种（r）-2-对硝基苯乙胺基-1-苯乙醇及其盐的合成方法
CN103232368B (zh) * 2013-04-18 2015-08-12 苏州永健生物医药有限公司 一种(r)-4-硝基苯乙基-(2-羟基-2-苯乙基)-氨基甲酸叔丁酯的合成方法
CN103232352B (zh) * 2013-05-11 2015-12-23 苏州永健生物医药有限公司 (r)-4-(2-(2-羟基-2-苯乙胺基)乙基)苯胺基甲酸叔丁基酯
CN105579057A (zh) * 2013-07-23 2016-05-11 阿勒根公司 包含与β-3-肾上腺素能受体激动剂组合的去氨加压素的方法和组合物
ITMI20131653A1 (it) * 2013-10-07 2015-04-08 Dipharma Francis Srl Forme cristalline di un agonista adrenergico
RU2550968C1 (ru) * 2013-11-29 2015-05-20 Федеральное государственное бюджетное учреждение "Научный центр акушерства, гинекологии и перинатологии имени академика В.И. Кулакова" Министерства здравоохранения Российской Федерации Комплексный способ лечения пациенток с хроническими рецидивирующими циститами и рефрактерным гиперактивным мочевым пузырем
WO2015155664A1 (fr) * 2014-04-08 2015-10-15 Suven Life Sciences Limited Procédé amélioré de préparation de 2-(2-aminothiazol-4-yl)-n-[4-(2-[[(2r)-2-hydroxy-2-phényléthyl] amino]-éthyl)phényl]acétamide
WO2015162536A1 (fr) * 2014-04-22 2015-10-29 Calyx Chemicals And Pharmaceuticals Ltd. Nouveau procédé de préparation de mirabégron et de son intermédiaire
CN104016943A (zh) * 2014-05-23 2014-09-03 苏州凯瑞医药科技有限公司 一种米拉贝隆的合成方法
CN104016877B (zh) * 2014-06-13 2017-02-15 南京海融制药有限公司 一种苯基乙酰胺类化合物及在制备米拉贝隆中的应用
CN104230840A (zh) * 2014-09-05 2014-12-24 安徽联创药物化学有限公司 米拉贝隆的合成方法
CA2967390A1 (fr) 2014-11-20 2016-05-26 Allergan, Inc. Procedes et compositions comprenant de la desmopressine combinee a un antagoniste du recepteur alpha-adrenergique
CN104496841B (zh) * 2014-11-26 2017-01-25 南京工业大学 一种米拉贝隆中间体的合成方法
CN104744292A (zh) * 2015-03-11 2015-07-01 南京工业大学 (r)-2-((4-硝基苯乙基)氨基)-2-氧代-1-苯乙基乙酸酯或其衍生物的制备方法
JP2018090490A (ja) 2015-03-31 2018-06-14 アステラス製薬株式会社 ミラベグロン含有医薬組成物
JP6618736B2 (ja) 2015-09-01 2019-12-11 沢井製薬株式会社 ミラベグロン含有錠剤、ミラベグロン含有製剤の製造方法及びミラベグロン含有造粒物の製造方法
CN106278909B (zh) * 2016-08-12 2022-07-15 浙江华海药业股份有限公司 一种米拉贝隆中间体的后处理方法
EP3360866B1 (fr) 2017-02-14 2019-01-02 Alfred E. Tiefenbacher (GmbH & Co. KG) Promédicaments mirabegron
KR102051132B1 (ko) * 2017-03-17 2019-12-02 주식회사 종근당 미라베그론 또는 이의 염을 포함하는 방출조절용 약제학적 조성물
KR101868438B1 (ko) 2017-04-13 2018-06-20 (주) 성운파마코피아 아미드 유도체의 제조방법
EP3636256B1 (fr) 2017-05-31 2024-07-03 SBI Pharmaceuticals Co., Ltd. Agent prophylactique ou thérapeutique destiné à la vessie hyperactive
KR20250099259A (ko) 2017-06-06 2025-07-01 유로반트 사이언시즈 게엠베하 과민성 방광의 치료를 위한 비베그론의 용도
KR102398639B1 (ko) 2017-06-20 2022-05-17 (주) 성운파마코피아 아미드 유도체의 염 및 그 제조방법
KR101937713B1 (ko) 2017-07-14 2019-01-14 주식회사 대웅제약 약제학적 제제 및 그 제조방법
WO2019013583A2 (fr) 2017-07-14 2019-01-17 주식회사 대웅제약 Préparation pharmaceutique et son procédé de préparation
TW202038963A (zh) 2018-12-05 2020-11-01 瑞士商優洛凡特科學公司 維貝隆（ｖｉｂｅｇｒｏｎ）於治療患有良性前列腺增生之男性中膀胱過動症症狀之用途
KR20200117091A (ko) 2019-04-02 2020-10-14 제이투에이치바이오텍 (주) 미라베그론 전구체 약물 화합물 및 이의 과민성 방광 질환의 치료 또는 개선을 위한 의약 용도
EP3722285B1 (fr) 2020-04-08 2022-03-30 Alfred E. Tiefenbacher (GmbH & Co. KG) Procédé de préparation de mirabegron énacarbile
CN113816864B (zh) * 2020-06-18 2024-03-29 南京正大天晴制药有限公司 一种(r)-2-羟基-n-[2-(4-氨基苯基)乙基]-2-苯乙胺的制备方法
KR20220081033A (ko) 2020-12-08 2022-06-15 주식회사 한서켐 미라베그론 α형 결정의 제조방법
EP4338729A1 (fr) 2022-09-19 2024-03-20 Sanovel Ilac Sanayi Ve Ticaret A.S. Comprimé comprenant du mirabegron
EP4410279A1 (fr) 2023-01-25 2024-08-07 Sanovel Ilac Sanayi Ve Ticaret A.S. Comprimé de film comprenant du mirabegron
KR20240171516A (ko) 2023-05-30 2024-12-09 주식회사 디앤아이바이오 미라베그론 서방정
US12097189B1 (en) 2024-02-09 2024-09-24 Astellas Pharma Inc. Pharmaceutical composition for modified release
TR2024008630A1 (tr) 2024-07-04 2026-01-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Mi̇rabegron i̇çeren modi̇fi̇ye salimli bi̇r tablet bi̇leşi̇mi̇
WO2026064392A1 (fr) 2024-09-17 2026-03-26 Flavostar Llc Combinaison de doses fixes de flovoxate et d'agonistes du récepteur adrénergique bêta-3, et formulations et procédés de fabrication associés

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07119189B2 (ja) 1989-09-28 1995-12-20 北陸製薬株式会社 光学活性なベンジルアルコール誘導体及びその用途
GB9107827D0 (en) 1991-04-12 1991-05-29 Fujisawa Pharmaceutical Co New ethanolamine derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same
IL104567A (en) 1992-02-03 1997-03-18 Fujisawa Pharmaceutical Co Ethanolamine derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
JPH06293664A (ja) 1993-04-05 1994-10-21 Fujisawa Pharmaceut Co Ltd β３−アドレナリン作動薬の新規医薬用途
AU6581294A (en) 1993-04-26 1994-11-21 Fujisawa Pharmaceutical Co., Ltd. Ethanolamine derivatives useful for the treatment of gastrointestinal disorders
JPH07228543A (ja) 1994-02-16 1995-08-29 Fujisawa Pharmaceut Co Ltd β３−アドレナリン作動薬の新規医薬用途
CZ126598A3 (cs) 1995-10-26 1998-09-16 Mitsubishi-Tokyo Pharmaceuticals, Inc. Fenylethanolaminové sloučeniny, způsob jejich výroby a farmaceutické prostředky s jejich obsahem
EP0932401A1 (fr) * 1996-07-01 1999-08-04 Sepracor, Inc. Procedes et compositions de traitement de l'incontinence urinaire par (r, r)-glycopyrrolate enrichi par enantiomere
CA2263659A1 (fr) 1996-08-19 1998-02-26 Kissei Pharmaceutical Co., Ltd. Remede therapeutique ou preventif contre l'incontinence ou l'elimination urinaire frequente
CA2302496C (fr) * 1997-08-28 2009-12-08 Mount Cook Biosciences, Inc. Therapie contre l'incontinence urinaire
KR100506568B1 (ko) 1997-10-17 2006-04-21 아스텔라스세이야쿠 가부시키가이샤 아미드유도체및이의염,및이를포함하는약제학적제제
ATE250570T1 (de) 1997-12-18 2003-10-15 Kissei Pharmaceutical Phenylaminoalkylcarbonsäure-derivate und medizinische zusammensetzungen, die diese enthalten
ATE275126T1 (de) * 1998-04-14 2004-09-15 Kissei Pharmaceutical 2-methylpropionsäure-derivate und sie enthaltende medizinische zubereitungen
MY126489A (en) 1998-07-08 2006-10-31 Kissei Pharmaceutical Phenoxyacetic acid derivatives and medicinal compositions containing the same
CA2362586A1 (fr) * 1999-02-12 2000-08-17 Genset S.A. Marqueurs bialleles derives de regions genomiques porteuses de genes intervenant dans le metabolisme de l'acide arachidonique
GB2356197A (en) 1999-10-12 2001-05-16 Merck & Co Inc Amide derivatives as beta 3 agonists
JP2001114736A (ja) * 1999-10-19 2001-04-24 Kissei Pharmaceut Co Ltd ２−アミノプロパノール誘導体
EP1258253A1 (fr) 2000-01-28 2002-11-20 Asahi Kasei Kabushiki Kaisha Nouveaux remedes et utilisation d'un agoniste beta3
AUPQ585000A0 (en) * 2000-02-28 2000-03-16 Fujisawa Pharmaceutical Co., Ltd. Aminoalcohol derivatives
AUPQ841300A0 (en) 2000-06-27 2000-07-20 Fujisawa Pharmaceutical Co., Ltd. New aminoalcohol derivatives
AR035605A1 (es) * 2000-12-11 2004-06-16 Bayer Corp Derivados de aminometil cromano di-sustituidos, un metodo para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la manufactura de medicamentos utiles como agonistas beta-3-adreno-receptores
US7342117B2 (en) 2001-10-30 2008-03-11 Astellas Pharma Inc. α-form or β-form crystal of acetanilide derivative
EP1879578A4 (fr) * 2005-03-21 2009-05-13 Dov Pharmaceutical Inc Methodes et compositions destinees au traitement de l'incontinence urinaire

Also Published As

Publication number Publication date
NZ539577A (en) 2007-06-29
USRE44872E1 (en) 2014-04-29
CY1111399T1 (el) 2015-08-05
NO20052691D0 (no) 2005-06-06
PT1559427E (pt) 2011-05-27
RU2321401C2 (ru) 2008-04-10
NO2015001I1 (no) 2015-01-19
KR20050072809A (ko) 2005-07-12
LU92218I9 (fr) 2019-01-17
BE2013C040I2 (fr) 2023-03-07
CY2013023I1 (el) 2015-10-07
IL168121A (en) 2011-12-29
CY2013023I2 (el) 2015-10-07
JPWO2004041276A1 (ja) 2006-03-02
HUS1300027I1 (hu) 2016-08-29
DK1559427T3 (da) 2011-04-26
NO334948B1 (no) 2014-08-04
US20110230530A1 (en) 2011-09-22
PL376771A1 (pl) 2006-01-09
NO2015001I2 (no) 2015-01-26
RU2005117367A (ru) 2006-01-20
PL211687B1 (pl) 2012-06-29
DE60336334D1 (de) 2011-04-21
WO2004041276A1 (fr) 2004-05-21
EP1559427A1 (fr) 2005-08-03
FR13C0032I1 (fr) 2013-08-09
AU2003284700B2 (en) 2009-05-28
MXPA05004925A (es) 2005-08-18
KR100967070B1 (ko) 2010-07-01
US7750029B2 (en) 2010-07-06
NL300599I2 (fr) 2017-01-03
ES2360353T3 (es) 2011-06-03
NO20052691L (no) 2005-07-15
CA2503570A1 (fr) 2004-05-21
CN100406011C (zh) 2008-07-30
US8835474B2 (en) 2014-09-16
BR0316080A (pt) 2005-09-27
EP1559427B1 (fr) 2011-03-09
CA2503570C (fr) 2011-04-19
CN1711085A (zh) 2005-12-21
EP1559427A4 (fr) 2007-05-30
US20090093529A1 (en) 2009-04-09
SI1559427T1 (sl) 2011-06-30
JP3815496B2 (ja) 2006-08-30
FR13C0032I2 (fr) 2014-03-07
ATE500827T1 (de) 2011-03-15
ZA200503510B (en) 2006-12-27
AU2003284700A1 (en) 2004-06-07
US20060115540A1 (en) 2006-06-01

Similar Documents

Publication Publication Date Title
BE2013C040I2 (fr)
LU92943I2 (fr) Ceftolozane ou un sel pharmaceutiquement acceptable, en particulier un sel d'acide sulfurique (zerbaxa)
EP1644009A4 (fr) Compositions et methodes destinees a augmenter l'activite de la telomerase
FR2843290B1 (fr) Dispositif et procede pour la mesure de l'elasticite d'un organe humain ou animal
DE60331187D1 (de) Kinaseinhibitoren
EE200100097A (et) Hingamisteede lima tootmise tõkestamine EGF-R antagonistide manustamise teel
WO2002085861A8 (fr) Composes d'imidazolidine et leur utilisation comme antagonistes de cxcr3
ITMI20041890A1 (it) Metodo per la compensazione della deriva in misure radar con l'ausilio di segnali radar di riferimento
BG108426A (bg) Нови производни на сулфоновата киселина
DK1585546T3 (da) KIM- 1- Antagonister og Brug til at Modulere Immunsystem
ATE345123T1 (de) Behandlung von angiogenesebezogenen krankheiten mit benzoyl phenylessigsäure derivaten
TR200201249T2 (tr) 15-hidroksieikosatetraenoik asitin heteroatomun araya girdiği analogları ve bunların kullanım yöntemleri.
FR2583282B1 (fr) Appareil portatif de mesure des pulsations cardiaques au cours de l'entrainement d'un athlete, notamment d'un coureur a pied
FR2835921B1 (fr) Utilisation d'une sonde capacitive pour determiner la biomasse de bacteries lactiques
DE3465306D1 (en) Disubstituted piperidines, processes for their preparation and pharmaceutical compositions containing them
ES2120251T3 (es) 3-alcoxicarbonil-tiadiazinonas cardioactivas.
EP1512972A4 (fr) Procede de mesure d'immunoreaction
FR2846676B1 (fr) Fondations d'un pylone ou similaire
DE69909666D1 (de) Vorrichtung zum Verbinden des Ankerkerns eines elastischen Gelenks mit einem Aussenteil
EP1620540A4 (fr) Plantes a taux ameliores d'un ou de plusieurs acides amines
FR2845285B1 (fr) Procede d'obtention d'un principe actif de stimulation du bronzage et principe actif obtenu
FR2849193B1 (fr) Procede pour tester l'etancheite d'une piece creuse
EA200000168A1 (ru) Фармацевтическая композиция, снижающая продуцирование белка мср-1
EP1540506A4 (fr) Construction d'un modele de reconnaissance de forme appliquee a l'exploration et a la production petrolieres
FR2799212B1 (fr) Appareil de traitement electrochimique de la surface interne d'alesages